article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

DAIC

Four heart rhythm organizations from around the globe developed the statement. It is also published in Heart Rhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores (MLWHF and EQ-5D) and many subdomains of these scores (e.g., See more details at TCTMD. versus patients on GDMT alone.

article thumbnail

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

Frontiers in Cardiovascular Medicine

Atrial fibrillation (AF) is the most common heart rhythm disorder in clinical practice. It worsens the quality of life of patients, leads to an increase in the mortality rate because of its association with a high risk of thromboembolic complications.

article thumbnail

Mainstay ablation procedure for atrial fibrillation shows substantial benefit over sham procedure

Medical Xpress - Cardiology

A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented Sept.

article thumbnail

Top Cardiology Conferences in 2024

Cardiology Update

European Heart Rhythm Association (EHRA) Congress Date: April 7-9, 2024 Location: Berlin, Germany and online Overview: The yearly gathering of the European Heart Rhythm Association (EHRA) unites scientists, healthcare professionals, and other stakeholders engaged in the global management of arrhythmias. Hashtag: #ACC24 3.

article thumbnail

Ninerafaxstat Well-Tolerated and Safe for Nonobstructive Hypertrophic Cardiomyopathy

DAIC

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S.